Blood-Based Insight
Plasma p-Tau217 offers a practical way to add amyloid-related biomarker information to cognitive evaluations.
FOR CLINICS AND CARE TEAMS
Gain Earlier Insight into Alzheimer's Biomarkers with a Simple Blood Test
Support clinical decision-making with accessible, science-driven biomarker insight designed to integrate into your workflow.
Supported by clinically validated p-Tau217 biomarker research with strong alignment to established diagnostic methods.
For clinician-directed use. Results are intended to support evaluation and should always be interpreted within the full clinical context.
Why This Matters
Alzheimer's-related changes in the brain can begin many years before symptoms appear. Blood-based biomarkers such as p-Tau217 may provide earlier insight into this process within a broader clinical evaluation.
Many patients are identified later in the disease process, when additional diagnostic steps are already underway. Earlier biomarker insight may help support more timely evaluation and planning.
Traditional diagnostic pathways may involve invasive procedures or more complex access to imaging. A simple blood draw can offer a more accessible entry point within a broader clinical evaluation.
At a glance
- Earlier insight may help support evaluation timing and care discussions.
- Blood-based biomarker testing can reduce friction in initial assessment pathways.
- Clinical interpretation remains essential for appropriate use and follow-up.
Clinical Value
ALZ Blood Test provides blood-based p-Tau217 biomarker insight intended to complement clinical assessment, not replace it.
PET-Aligned Performance
Supporting validation materials report approximately 95% sensitivity and specificity relative to amyloid PET-aligned reference thresholds.
Supports Earlier Conversations
Results may help guide clinical discussions, follow-up planning, and consideration of additional testing when appropriate.
Non-Invasive Workflow
A blood draw may be easier to integrate into care pathways than more invasive or complex diagnostic approaches.
- Results typically available within 1–3 days after sample processing
This test does not establish a diagnosis on its own. Results should be interpreted by a clinician alongside symptoms, history, and other relevant findings.
Designed for use within clinician-directed evaluation workflows.
When to Use
Patients Age 45+
For patients age 45+ presenting with cognitive concerns where biomarker context may support evaluation.
Suspected Alzheimer's Disease
When clinical presentation raises the question of Alzheimer's disease and additional insight may be useful.
Differential Evaluation
To support the differentiation of potential causes of cognitive decline within a broader workup.
Results Overview
Reports are designed to present clear interpretation categories that can support next-step discussions.
Lower Likelihood
A negative result is associated with a lower likelihood of Alzheimer's pathology.
Consider Further Evaluation
An intermediate result may warrant consideration of additional assessment based on the full clinical picture.
Consistent with Amyloid Pathology
A positive result is consistent with amyloid pathology and should be reviewed within the broader clinical context.
Results should be interpreted within the full clinical context.
How It Works
The onboarding process is designed to help clinics move from registration to ordering with minimal disruption.
1
Register as a provider
Complete the registration form to begin the onboarding process for your practice.
2
Receive access credentials and ordering link
Your team receives the information needed to activate ordering and reporting access.
3
Order tests and collect samples
Collect samples in-office or use the available phlebotomy network based on your workflow.
4
Receive results through the reporting platform
Access completed reports through the reporting platform for clinician review and follow-up.
Designed to Integrate Into Your Practice
Testing can be incorporated into routine visits and standard blood draw workflows without adding operational complexity.
Simple Blood Draw
No specialized procedures required for sample collection.
Flexible Collection
Collect in-office or use a phlebotomy network based on your workflow.
Streamlined Ordering
Order and manage tests through a secure platform.
Clear Reporting
Receive structured results designed for clinical review and follow-up.
Why ALZ Blood Test
Designed for Clinical Usability
Built to fit real-world clinic workflows, from onboarding through result delivery.
Clear Interpretation Thresholds
Reporting is structured to support consistent review and discussion of result categories.
Supports Confident Decision-Making
Provides practical biomarker context that may inform next steps when used with clinical judgment.
Backed by Biomarker Research
Grounded in validated p-Tau217 biomarker research and supporting clinical performance materials.
Review Clinical Evidence and Reporting
Explore sample reports, validation data, and clinical materials to understand how results are presented and used in practice.
What Happens After Registration
- Access code and ordering link sent within 1-2 business days
- Account activation email for the ELIS platform
- Team follow-up if additional information is needed
- Ability to begin placing orders once activated
ALZ BLOOD TEST
Know Early. Act Confidently.
Providing earlier insight so clinicians can make informed decisions with confidence.